NEW YORK (GenomeWeb News) – Fluidigm said that it could receive up to an additional $3.2 million in proceeds from its minority stake in Verinata, acquired by Illumina in February for up to $450 million. In March Fluidigm received proceeds of $3.1 million in exchange for its ownership in Verinata, resulting in a gain of $1.8 million, it said in its Form 10-Q filed this week. Fluidigm added that it could receive the additional $3.2 million in proceeds if "certain milestone payments become payable."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: factors affecting the success of whole-genome sequencing for routine clinical diagnosis, and more.

A large meta-analysis from an international team reports that nature and nurture have about an equal overall influence on human traits.

The Lasker Foundation's Claire Pomeroy laments the state of NIH funding at Forbes.

Social media is changing how scientists discuss research, as tweets from University of Chicago's Yoav Gilad about a Mouse ENCODE paper have shown, Nature reports.